Vedanta Biosciences raises $16.6 mln
Vedanta Biosciences said Sept. 23 that it raised $16.6 million in Series C-2 financing. Participants include QUAD Investment Management, SV Investment Corp, Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment Co Ltd, FC Capital, and SymBiosis LLC, who joined the previously announced Series C investors, including the Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Rock Springs Capital, JSR Corp, Shumway Capital, Invesco Asset Management, Health for Life (Seventure Partners), and founder PureTech Health. Vedanta is developing therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria.
23 September 2019•4 mins read
